Statera Biopharma (STAB) 10-Q 14 Nov 19 2019 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Oct. 31, 2019
Document Information [Line Items]
Entity Registrant Name	CLEVELAND BIOLABS INC
Entity Central Index Key	0001318641
Trading Symbol	cbli
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		11,298,239
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Amendment Flag	false
Title of 12(b) Security	Common stock, par value $0.005

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 1,487,388	$ 3,617,234
Short-term investments	426,915	503,810
Accounts receivable	210,805	251,846
Other current assets	67,552	103,397
Total current assets	2,192,660	4,476,287
Equipment, net	17,445	27,747
Other long-term assets	18,667	30,373
Total assets	2,228,772	4,534,407
Current liabilities:
Accounts payable	99,529	139,120
Accrued expenses	441,692	694,164
Accrued warrant liability	24,461	78,637
Total current liabilities	565,682	911,921
Non-current liabilities		8,459
Total liabilities	565,682	920,380
Stockholders’ equity:
Preferred stock, $.005 par value; 1,000,000 shares authorized as of September 30, 2019 and December 31, 2018; 0 shares issued and outstanding as of September 30, 2019 and December 31, 2018
Common stock, $.005 par value; 25,000,000 shares authorized as of September 30, 2019 and December 31, 2018; 11,298,239 shares issued and outstanding as of September 30, 2019 and December 31, 2018	56,487	56,487
Additional paid-in capital	163,161,523	163,161,523
Accumulated other comprehensive loss	(582,904)	(611,370)
Accumulated deficit	(165,998,275)	(164,058,585)
Total Cleveland BioLabs, Inc. stockholders’ deficit	(3,363,169)	(1,451,945)
Noncontrolling interest in stockholders’ equity	5,026,259	5,065,972
Total stockholders’ equity	1,663,090	3,614,027
Total liabilities and stockholders’ equity	$ 2,228,772	$ 4,534,407

Consolidated Condensed Balanc_2

Consolidated Condensed Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
Preferred stock, par value (in dollars per share)	$ 0.005	$ 0.005
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.005	$ 0.005
Common stock, shares authorized (in shares)	25,000,000	25,000,000
Common stock, shares issued (in shares)	11,298,239	11,298,239
Common stock, shares outstanding (in shares)	11,298,239	11,298,239

Consolidated Condensed Statemen

Consolidated Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenues:
Grants and contracts	$ 269,635	$ 283,307	$ 744,521	$ 902,474
Operating expenses:
Research and development	262,410	839,413	1,375,409	3,084,790
General and administrative	525,621	711,660	1,449,281	1,989,596
Total operating expenses	788,031	1,551,073	2,824,690	5,074,386
Loss from operations	(518,396)	(1,267,766)	(2,080,169)	(4,171,912)
Other income (expense):
Interest and other income	14,246	16,191	32,528	109,591
Foreign exchange gain (loss)	251	1,772	(808)	2,868
Change in value of warrant liability	36,532	121,442	54,176	800,055
Total other income	51,029	139,405	85,896	912,514
Net loss	(467,367)	(1,128,361)	(1,994,273)	(3,259,398)
Net loss attributable to noncontrolling interests	17,448	23,917	54,583	79,307
Net loss attributable to Cleveland BioLabs, Inc.	$ (449,919)	$ (1,104,444)	$ (1,939,690)	$ (3,180,091)
Net loss attributable to common stockholders per share of common stock, basic and diluted (in dollars per share)	$ (0.04)	$ (0.10)	$ (0.17)	$ (0.28)
Weighted average number of shares used in calculating net loss per share, basic and diluted (in shares)	11,298,239	11,298,239	11,298,239	11,292,365

Consolidated Condensed Statem_2

Consolidated Condensed Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Net loss including noncontrolling interests	$ (467,367)	$ (1,128,361)	$ (1,994,273)	$ (3,259,398)
Other comprehensive loss:
Unrealized gain (loss) on short-term investments		(137)		1,841
Foreign currency translation adjustment	(11,994)	(34,788)	43,336	(109,640)
Comprehensive loss including noncontrolling interests	(479,361)	(1,163,286)	(1,950,937)	(3,367,197)
Comprehensive loss attributable to noncontrolling interests	21,281	35,039	39,713	114,664
Comprehensive loss attributable to Cleveland BioLabs, Inc.	$ (458,080)	$ (1,128,247)	$ (1,911,224)	$ (3,252,533)

Consolidated Condensed Statem_3

Consolidated Condensed Statement of Stockholders' Equity (Unaudited) - USD ($)	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Common Stock [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Total
Balance (in shares) at Dec. 31, 2017				11,279,834
Beginning balance at Dec. 31, 2017	$ (516,457)	$ (160,446,612)	$ 5,208,644	$ 56,395		$ 163,106,400	$ 7,408,370
Exercise of warrants (in shares)				18,405
Exercise of warrants				$ 92		55,123	55,215
Net loss		(1,224,610)	(33,842)				(1,258,452)
Unrealized loss on short-term investments	1,477						1,477
Foreign currency translation	4,681		2,192				6,873
Balance (in shares) at Mar. 31, 2018				11,298,239
Ending balance at Mar. 31, 2018	(510,299)	(161,671,222)	5,176,994	$ 56,487		163,161,523	6,213,483
Balance (in shares) at Dec. 31, 2017				11,279,834
Beginning balance at Dec. 31, 2017	(516,457)	(160,446,612)	5,208,644	$ 56,395		163,106,400	7,408,370
Net loss							(3,259,398)
Foreign currency translation							(109,640)
Balance (in shares) at Sep. 30, 2018				11,298,239
Ending balance at Sep. 30, 2018	(588,899)	(163,626,703)	5,093,980	$ 56,487		163,161,523	4,096,388
Balance (in shares) at Mar. 31, 2018				11,298,239
Beginning balance at Mar. 31, 2018	(510,299)	(161,671,222)	5,176,994	$ 56,487		163,161,523	6,213,483
Net loss		(851,037)	(21,548)				(872,585)
Unrealized loss on short-term investments	501						501
Foreign currency translation	(55,298)		(26,427)				(81,725)
Balance (in shares) at Jun. 30, 2018				11,298,239
Ending balance at Jun. 30, 2018	(565,096)	(162,522,259)	5,129,019	$ 56,487		163,161,523	5,259,674
Net loss		(1,104,444)	(23,917)				(1,128,361)
Unrealized loss on short-term investments	(137)						(137)
Foreign currency translation	(23,666)		(11,122)				(34,788)
Balance (in shares) at Sep. 30, 2018				11,298,239
Ending balance at Sep. 30, 2018	(588,899)	(163,626,703)	5,093,980	$ 56,487		163,161,523	4,096,388
Balance (in shares) at Dec. 31, 2018				11,298,239
Beginning balance at Dec. 31, 2018	(611,370)	(164,058,585)	5,065,972	$ 56,487		163,161,523	3,614,027
Net loss		(872,943)	(20,369)				(893,312)
Foreign currency translation	26,759		13,991				40,750
Balance (in shares) at Mar. 31, 2019				11,298,239
Ending balance at Mar. 31, 2019	(584,611)	(164,931,528)	5,059,594	$ 56,487		163,161,523	2,761,465
Balance (in shares) at Dec. 31, 2018				11,298,239
Beginning balance at Dec. 31, 2018	(611,370)	(164,058,585)	5,065,972	$ 56,487		163,161,523	3,614,027
Net loss							(1,994,273)
Foreign currency translation							43,336
Balance (in shares) at Sep. 30, 2019				11,298,239
Ending balance at Sep. 30, 2019	(582,904)	(165,998,275)	5,026,259	$ 56,487		163,161,523	1,663,090
Balance (in shares) at Mar. 31, 2019				11,298,239
Beginning balance at Mar. 31, 2019	(584,611)	(164,931,528)	5,059,594	$ 56,487		163,161,523	2,761,465
Net loss		(616,828)	(16,766)				(633,594)
Foreign currency translation	9,868		4,712				14,580
Balance (in shares) at Jun. 30, 2019				11,298,239
Ending balance at Jun. 30, 2019	(574,743)	(165,548,356)	5,047,540	$ 56,487		163,161,523	2,142,451
Net loss		(449,919)	(17,448)				(467,367)
Foreign currency translation	(8,161)		(3,833)				(11,994)
Balance (in shares) at Sep. 30, 2019				11,298,239
Ending balance at Sep. 30, 2019	$ (582,904)	$ (165,998,275)	$ 5,026,259	$ 56,487		$ 163,161,523	$ 1,663,090

Consolidated Condensed Statem_4

Consolidated Condensed Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities:
Net loss	$ (1,994,273)	$ (3,259,398)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	10,303	14,084
Non-cash investment income		(30,312)
Gain on equipment disposal	(43,300)	(35,274)
Change in value of warrant liability	(54,176)	(800,055)
Changes in operating assets and liabilities:
Accounts receivable and other current assets	77,152	482,860
Other long-term assets	11,858	(3,386)
Accounts payable and accrued expenses	(306,499)	190,405
Net cash used in operating activities	(2,298,935)	(3,441,076)
Cash flows from investing activities:
Purchase of short-term investments	(806,713)	(6,795,170)
Sale of short-term investments	921,957	10,341,526
Purchase of equipment		(21,376)
Proceeds from sale of equipment	43,300	35,770
Net cash provided by investing activities	158,544	3,560,750
Cash flows from financing activities:
Exercise of warrants		55,215
Net cash provided by financing activities		55,215
Effect of exchange rate change on cash and equivalents	10,545	(26,698)
Increase (decrease) in cash and cash equivalents	(2,129,846)	148,191
Cash and cash equivalents at beginning of period	3,617,234	4,230,548
Cash and cash equivalents at end of period	$ 1,487,388	$ 4,378,739

Note 1 - Description of Busines

Note 1 - Description of Business	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Cleveland BioLabs, Inc. (" CBLI Company TLR CBLI was incorporated in Delaware in June 2003 U.S. Russia two one 612, BioLab 612 2012 September 2019 Panacela RUSNANO 2011. In addition, the Company has an investment in Genome Protection, Inc. (" GPI not 50% September 30, 2019 no

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Basis of Presentation and Consolidation The accompanying unaudited consolidated condensed financial statements include the accounts of CBLI, BioLab 612, The consolidated condensed balance sheet as of December 31, 2018 GAAP 10 8 X SEC 10 December 31, 2018 2018 Form 10 In the opinion of the Company’s management, any adjustments contained in the accompanying unaudited consolidated financial statements are of a normal recurring nature, and are necessary to fairly present the financial position of the Company as of September 30, 2019 three nine September 30, 2019 2018 nine September 30, 2019 2018 not may At September 30, 2019 $1.9 September 2020. no not Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (" FASB not not In February 2016, 2016 02, 842 ASU 2016 02 2016 02 12 2016 02 December 15, 2018, 2019 no Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Short-Term Investments The Company’s short-term investments are classified as held to maturity and are recorded at amortized cost. Short-term investments consisted of $0.4 three one Significant Customers and Accounts Receivable The following table presents our revenue by customer, on a proportional basis, for the three nine September 30, 2019 2018 Three Months Ended Nine Months Ended September 30, September 30, Customer 2019 2018 Variance 2019 2018 Variance Department of Defense 90.0 % 43.7 % 46.3 % 60.2 % 50.0 % -10.2 % Incuron 10.0 % 56.3 % (46.3 )% 39.8 % 50.0 % -10.2 % Total 100.0 % 100.0 % 0.0 % 100.0 % 100.0 % 0.0 % Our current Department of Defense (" DoD 2019 2020, may Accounts receivable consist of amounts due under reimbursement contracts with these customers. The Company extends unsecured credit to customers under normal trade agreements, which generally require payment within 30 Other Comprehensive Income (Loss) The Company applies the Accounting Standards Codification (" Codification nine September 30, 2019 Gains and losses on foreign exchange translations Beginning balance $ (611,370 ) Other comprehensive income (loss) before reclassifications 28,466 Amounts reclassified from accumulated other comprehensive loss — Ending balance $ (582,904 ) Accounting for Stock-Based Compensation The Cleveland Biolabs, Inc. Equity Incentive Plan, adopted in 2018 Plan September 30, 2019 597,557 461,268 136,289 2018 100,000 no 10 The 2013 ESPP may September 30, 2019 625,000 January 1 10% December 31st 100,000 15% 85% The Company utilizes the Black-Scholes valuation model for estimating the fair value of all stock options granted where the vesting period is based on length of service or performance, while a Monte Carlo simulation model is used for estimating the fair value of stock options with market-based vesting conditions. No nine September 30, 2019 September 30, 2018 Income Taxes No three nine September 30, 2019 2018 not 2019 not 2018 At December 31, 2018 $144.0 $139.7 not 2023, $4.2 not 2024. $89.8 not 2027 $0.3 not 2022. 6,459,948 July 9, 2015 60.2% 382 $124.8 $3.65 $73.4 $0.3 July 9, 2015, Earnings (Loss) per Share Basic net loss per share of common stock excludes dilution for potential common stock issuances and is computed by dividing net loss by the weighted average number of shares outstanding for the period. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. Diluted net loss per share is identical to basic net loss per share as potentially dilutive securities have been excluded from the calculation of diluted net loss per common share because the inclusion of such securities would be antidilutive. The Company has excluded the following securities from the calculation of diluted net loss per share because all such securities were antidilutive for the periods presented. Additionally, there were no September 30, 2019 As of September 30, Common Equivalent Securities 2019 2018 Warrants 327,253 528,054 Options 136,289 172,528 Total 463,542 700,582 Contingencies From time to time, the Company may not

Note 3 - Fair Value of Financia

Note 3 - Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Fair Value Disclosures [Text Block]	3. The Company measures and records warrant liabilities at fair value in the accompanying financial statements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three • Level 1 • Level 2 • Level 3 no Cash equivalents include United States Treasury Notes with original maturities of three three The valuation methodologies used to measure the fair value of the Company’s assets and instruments classified in stockholders’ equity are described as follows: U.S. Treasury Notes and money market funds included in cash equivalents and short-term investments are valued at the closing price reported by an actively traded exchange and are included as Level 1 2 The following tables represent the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis. As of September 30, 2019 Level 1 Level 2 Level 3 Total Assets: Cash and cash equivalents $ — $ — $ — $ — Short-term investments — 426,915 — 426,915 Total assets $ — $ 426,915 $ — $ 426,915 Liabilities: Accrued warrant liability $ — $ — $ 24,461 $ 24,461 As of December 31, 2018 Level 1 Level 2 Level 3 Total Assets: Cash and cash equivalents $ 1,130 $ — $ — $ 1,130 Short-term investments — 503,810 — 503,810 Total assets $ 1,130 $ 503,810 $ — $ 504,940 Liabilities: Accrued warrant liability $ — $ — $ 78,637 $ 78,637 The Company uses the Black-Scholes model to measure the accrued warrant liability. The following are the assumptions used to measure the accrued warrant liability which were determined in a manner consistent with grants of options to purchase common stock: September 30, 2019 December 31, 2018 Stock Price $1.01 $1.01 Exercise Price $3.64 - $20.40 $3.64 - $24.40 Term in years 1.29 – 1.85 0.04-2.60 Volatility 78.36%-85.90% 88.07%-108.18% Annual rate of quarterly dividends —% —% Discount rate- bond equivalent yield 1.65% - 1.71% 0.12% - 2.48% The following table sets forth a summary of changes in the fair value of the Company’s Level 3 Three Months Ended Three Months Ended September 30, 2019 September 30, 2018 Accrued Warrant Liability Accrued Warrant Liability Beginning Balance $ 60,993 $ 362,842 Total (gains) or losses, realized and unrealized, included in earnings (1) (36,532 ) (121,442 ) Issuances — — Settlements — — Ending Balance $ 24,461 $ 241,400 Nine Months Ended Nine Months Ended September 30, 2019 September 30, 2018 Accrued Warrant Liability Accrued Warrant Liability Beginning Balance $ 78,637 $ 1,041,455 Total (gains) or losses, realized and unrealized, included in earnings (1) (54,176 ) (800,055 ) Issuances — — Settlements — — Ending Balance $ 24,461 $ 241,400 ( 1 Unrealized gains or losses related to the accrued warrant liability were included as change in value of accrued warrant liability. There were no three nine September 30, 2019 2018 As of September 30, 2019 December 31, 2018 no The Company considers the accrued warrant liability to be Level 3 September 30, 2019 1.29 1.85 Management believes the value of the accrued warrant liability is more sensitive to a change in the Company’s stock price at the end of the respective reporting period as opposed to a change in the unobservable input described above. The carrying amounts of the Company’s short-term financial instruments, which include cash and cash equivalents, accounts receivable and accounts payable, approximate their fair values due to their short maturities.

Note 4 - Stockholders' Equity

Note 4 - Stockholders' Equity	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	4. The Company has granted options to purchase shares of common stock. The following is a summary of option award activity during the nine September 30, 2019 Total Stock Options Outstanding Weighted Average Exercise Price per Share December 31, 2018 160,076 $ 35.92 Granted — — Vested — — Forfeited, Canceled (23,787 ) 11.85 September 30, 2019 136,289 $ 40.12 The following is a summary of outstanding stock options as of September 30, 2019 As of September 30, 2019 Stock Options Outstanding Vested Stock Options Quantity 136,289 136,289 Weighted Average Exercise Price $ 40.12 $ 40.12 Weighted Average Remaining Contractual Term (in Years) 3.7 3.7 Intrinsic Value $ — $ — For the nine September 30, 2019 2018 no September 30, 2019 2018 $ 0 As of September 30, 2019 no not

Note 5 - Warrants

Note 5 - Warrants	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Derivative Instruments and Hedging Activities Disclosure [Text Block]	5. In connection with previous sales of the Company’s common stock and the issuance of debt instruments, warrants were issued which presently have exercise prices ranging from $3.64 $20.40. one seven The following table summarizes the activity in our outstanding warrants since December 31, 2018 Number of Warrants Weighted Average Exercise Price December 31, 2018 528,054 $ 10.90 Granted — — Exercised — — Forfeited, Canceled (200,801 ) 14.18 September 30, 2019 327,253 $ 8.89

Note 6 - Significant Alliances

Note 6 - Significant Alliances and Related Parties	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	6. Roswell Park Cancer Institute The Company has entered into several agreements with Roswell Park Cancer Institute (" RPCI 1 1 CBL0137 $9,367 $67,318 three nine September 30, 2019 $138,817 $187,262 three nine September 30, 2018 $7,925 $0 September 30, 2019 2018 $0 $214,429 September 30, 2019 2018 The Cleveland Clinic CBLI has entered into an exclusive license agreement with The Cleveland Clinic pursuant to which CBLI was granted an exclusive license to The Cleveland Clinic’s research base underlying our therapeutic platform and certain product candidates licensed to Panacela. CBLI has the primary responsibility to fund all newly developed patents. However, The Cleveland Clinic retains ownership of those patents covered by the agreement. CBLI also agreed to use commercially diligent efforts to bring one August 6, 2018, no nine September 30, 2019 2018 The Company incurred $30,710 $0 nine September 30, 2019 2018 Buffalo BioLabs and Incuron Our CSO, Dr. Andrei Gudkov, has business relationships with Buffalo BioLabs, LLC (" BBL $129 $129 three nine September 30, 2019 $122,929 $454,937 three nine September 30, 2018 $0 $53,000 September 30, 2019 2018 $0 $20,808 $11,553 $34,659 three nine September 30, 2019 September 30, 2018 $219,108 $206,747, $16,957 $4,596 September 30, 2019 2018 Dr. Gudkov is also an uncompensated member of the board of directors for Incuron. Pursuant to master service and development agreements we have with Incuron, the Company performs various research, business development, clinical advisory, and management services for Incuron. The Company recognized revenue of $26,928 $295,958 three nine September 30, 2019 $199,324 $291,445 three nine September 30, 2018 $0 $2,268 three nine September 30, 2019 $1,134 $4,044 three nine September 30, 2018 $32,512 $13,457 September 30, 2019 2018 Genome Protection GPI incurred $54,700 $149,550 three nine September 30, 2019 $0 September 30, 2019 $39,083 $39,083 three nine September 30, 2018, $20,853 September 30, 2018. $1,178 $4,209 three nine September 30, 2019 $675 $675 three nine September 30, 2018,

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation and Consolidation The accompanying unaudited consolidated condensed financial statements include the accounts of CBLI, BioLab 612, The consolidated condensed balance sheet as of December 31, 2018 GAAP 10 8 X SEC 10 December 31, 2018 2018 Form 10 In the opinion of the Company’s management, any adjustments contained in the accompanying unaudited consolidated financial statements are of a normal recurring nature, and are necessary to fairly present the financial position of the Company as of September 30, 2019 three nine September 30, 2019 2018 nine September 30, 2019 2018 not may At September 30, 2019 $1.9 September 2020. no not
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (" FASB not not In February 2016, 2016 02, 842 ASU 2016 02 2016 02 12 2016 02 December 15, 2018, 2019 no
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Marketable Securities, Policy [Policy Text Block]	Short-Term Investments The Company’s short-term investments are classified as held to maturity and are recorded at amortized cost. Short-term investments consisted of $0.4 three one
Receivable [Policy Text Block]	Significant Customers and Accounts Receivable The following table presents our revenue by customer, on a proportional basis, for the three nine September 30, 2019 2018 Three Months Ended Nine Months Ended September 30, September 30, Customer 2019 2018 Variance 2019 2018 Variance Department of Defense 90.0 % 43.7 % 46.3 % 60.2 % 50.0 % -10.2 % Incuron 10.0 % 56.3 % (46.3 )% 39.8 % 50.0 % -10.2 % Total 100.0 % 100.0 % 0.0 % 100.0 % 100.0 % 0.0 % Our current Department of Defense (" DoD 2019 2020, may Accounts receivable consist of amounts due under reimbursement contracts with these customers. The Company extends unsecured credit to customers under normal trade agreements, which generally require payment within 30
Comprehensive Income, Policy [Policy Text Block]	Other Comprehensive Income (Loss) The Company applies the Accounting Standards Codification (" Codification nine September 30, 2019 Gains and losses on foreign exchange translations Beginning balance $ (611,370 ) Other comprehensive income (loss) before reclassifications 28,466 Amounts reclassified from accumulated other comprehensive loss — Ending balance $ (582,904 )
Share-based Payment Arrangement [Policy Text Block]	Accounting for Stock-Based Compensation The Cleveland Biolabs, Inc. Equity Incentive Plan, adopted in 2018 Plan September 30, 2019 597,557 461,268 136,289 2018 100,000 no 10 The 2013 ESPP may September 30, 2019 625,000 January 1 10% December 31st 100,000 15% 85% The Company utilizes the Black-Scholes valuation model for estimating the fair value of all stock options granted where the vesting period is based on length of service or performance, while a Monte Carlo simulation model is used for estimating the fair value of stock options with market-based vesting conditions. No nine September 30, 2019 September 30, 2018
Income Tax, Policy [Policy Text Block]	Income Taxes No three nine September 30, 2019 2018 not 2019 not 2018 At December 31, 2018 $144.0 $139.7 not 2023, $4.2 not 2024. $89.8 not 2027 $0.3 not 2022. 6,459,948 July 9, 2015 60.2% 382 $124.8 $3.65 $73.4 $0.3 July 9, 2015,
Earnings Per Share, Policy [Policy Text Block]	Earnings (Loss) per Share Basic net loss per share of common stock excludes dilution for potential common stock issuances and is computed by dividing net loss by the weighted average number of shares outstanding for the period. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. Diluted net loss per share is identical to basic net loss per share as potentially dilutive securities have been excluded from the calculation of diluted net loss per common share because the inclusion of such securities would be antidilutive. The Company has excluded the following securities from the calculation of diluted net loss per share because all such securities were antidilutive for the periods presented. Additionally, there were no September 30, 2019 As of September 30, Common Equivalent Securities 2019 2018 Warrants 327,253 528,054 Options 136,289 172,528 Total 463,542 700,582
Commitments and Contingencies, Policy [Policy Text Block]	Contingencies From time to time, the Company may not

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, Customer 2019 2018 Variance 2019 2018 Variance Department of Defense 90.0 % 43.7 % 46.3 % 60.2 % 50.0 % -10.2 % Incuron 10.0 % 56.3 % (46.3 )% 39.8 % 50.0 % -10.2 % Total 100.0 % 100.0 % 0.0 % 100.0 % 100.0 % 0.0 %
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Gains and losses on foreign exchange translations Beginning balance $ (611,370 ) Other comprehensive income (loss) before reclassifications 28,466 Amounts reclassified from accumulated other comprehensive loss — Ending balance $ (582,904 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	As of September 30, Common Equivalent Securities 2019 2018 Warrants 327,253 528,054 Options 136,289 172,528 Total 463,542 700,582

Note 3 - Fair Value of Financ_2

Note 3 - Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Fair Value, by Balance Sheet Grouping [Table Text Block]	As of September 30, 2019 Level 1 Level 2 Level 3 Total Assets: Cash and cash equivalents $ — $ — $ — $ — Short-term investments — 426,915 — 426,915 Total assets $ — $ 426,915 $ — $ 426,915 Liabilities: Accrued warrant liability $ — $ — $ 24,461 $ 24,461 As of December 31, 2018 Level 1 Level 2 Level 3 Total Assets: Cash and cash equivalents $ 1,130 $ — $ — $ 1,130 Short-term investments — 503,810 — 503,810 Total assets $ 1,130 $ 503,810 $ — $ 504,940 Liabilities: Accrued warrant liability $ — $ — $ 78,637 $ 78,637
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	September 30, 2019 December 31, 2018 Stock Price $1.01 $1.01 Exercise Price $3.64 - $20.40 $3.64 - $24.40 Term in years 1.29 – 1.85 0.04-2.60 Volatility 78.36%-85.90% 88.07%-108.18% Annual rate of quarterly dividends —% —% Discount rate- bond equivalent yield 1.65% - 1.71% 0.12% - 2.48%
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Three Months Ended Three Months Ended September 30, 2019 September 30, 2018 Accrued Warrant Liability Accrued Warrant Liability Beginning Balance $ 60,993 $ 362,842 Total (gains) or losses, realized and unrealized, included in earnings (1) (36,532 ) (121,442 ) Issuances — — Settlements — — Ending Balance $ 24,461 $ 241,400 Nine Months Ended Nine Months Ended September 30, 2019 September 30, 2018 Accrued Warrant Liability Accrued Warrant Liability Beginning Balance $ 78,637 $ 1,041,455 Total (gains) or losses, realized and unrealized, included in earnings (1) (54,176 ) (800,055 ) Issuances — — Settlements — — Ending Balance $ 24,461 $ 241,400

Note 4 - Stockholders' Equity (

Note 4 - Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Total Stock Options Outstanding Weighted Average Exercise Price per Share December 31, 2018 160,076 $ 35.92 Granted — — Vested — — Forfeited, Canceled (23,787 ) 11.85 September 30, 2019 136,289 $ 40.12
Share-based Compensation Arrangements by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]	As of September 30, 2019 Stock Options Outstanding Vested Stock Options Quantity 136,289 136,289 Weighted Average Exercise Price $ 40.12 $ 40.12 Weighted Average Remaining Contractual Term (in Years) 3.7 3.7 Intrinsic Value $ — $ —

Note 5 - Warrants (Tables)

Note 5 - Warrants (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Schedule of Outstanding Warrants [Table Text Block]	Number of Warrants Weighted Average Exercise Price December 31, 2018 528,054 $ 10.90 Granted — — Exercised — — Forfeited, Canceled (200,801 ) 14.18 September 30, 2019 327,253 $ 8.89

Note 1 - Description of Busin_2

Note 1 - Description of Business (Details Textual)	9 Months Ended
	Sep. 30, 2019
BioLab 612 [Member]
Number of Wholly Owned Subsidiaries	1
GPI [Member]
Equity Method Investment, Ownership Percentage	50.00%

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	Jul. 09, 2015	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Cash, Cash Equivalents, and Short-term Investments, Total		$ 1,900,000		$ 1,900,000
Short-term Investments, Total		426,915		$ 426,915		$ 503,810
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				0	0
Income Tax Expense (Benefit), Total		0	$ 0	$ 0	$ 0
Sale of Stock, Number of Shares Issued in Transaction	6,459,948
Percentage of Common Shares Owned by Investor	60.20%
Domestic Tax Authority [Member]
Operating Loss Carryforwards, Total		124,800,000		124,800,000		144,000,000
Operating Loss Carryforwards, Amount Subject to Expriation						139,700,000
Tax Credit Carryforward, Amount		3,650,000		3,650,000		4,200,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards, Total		73,400,000		73,400,000		89,800,000
Tax Credit Carryforward, Amount		$ 300,000		$ 300,000		$ 300,000
The Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		597,557		597,557
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		461,268		461,268
Common Stock, Capital Shares Reserved for Future Issuance		136,289		136,289
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee				100,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				10 years
The ESPP [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		625,000		625,000
Percentage of Common Stock Outstanding of Preceding Year				10.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Limited Per Year		$ 100,000		$ 100,000
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate		15.00%		15.00%
Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date				85.00%
Certificates of Deposit [Member]
Short-term Investments, Total		$ 400,000		$ 400,000

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Customers and Accounts Receivable (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Percentage of revenue	100.00%	100.00%	100.00%	100.00%
Variance	0.00%		0.00%
Department of Defense [Member]
Percentage of revenue	90.00%	43.70%	60.20%	50.00%
Variance	46.30%		10.20%
Incuron [Member]
Percentage of revenue	10.00%	56.30%	39.80%	50.00%
Variance	(46.30%)		10.20%

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Other Comprehensive Income (Loss) (Details)	9 Months Ended
	Sep. 30, 2019USD ($)
Beginning balance	$ 3,614,027
Ending balance	1,663,090
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Beginning balance	(611,370)
Other comprehensive income (loss) before reclassifications	28,466
Amounts reclassified from accumulated other comprehensive loss
Ending balance	$ (582,904)

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Antidilutive securities (in shares)	463,542	700,582
Warrant [Member]
Antidilutive securities (in shares)	327,253	528,054
Share-based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)	136,289	172,528

Note 3 - Fair Value of Financ_3

Note 3 - Fair Value of Financial Instruments (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Fair Value Measurement with Unobservable Inputs, Liability, Realized Gain (Loss)	$ 0	$ 0	$ 0	$ 0
Assets, Fair Value Disclosure	$ 426,915		$ 426,915		$ 504,940
Minimum [Member]
Warrants and Rights Outstanding, Term	1 year		1 year
Maximum [Member]
Warrants and Rights Outstanding, Term	7 years		7 years
Accrued Warrant Liability [Member] | Minimum [Member]
Warrants and Rights Outstanding, Term	1 year 105 days		1 year 105 days
Accrued Warrant Liability [Member] | Maximum [Member]
Warrants and Rights Outstanding, Term	1 year 310 days		1 year 310 days
Fair Value, Nonrecurring [Member]
Assets, Fair Value Disclosure	$ 0		$ 0		0
Financial and Nonfinancial Liabilities, Fair Value Disclosure	$ 0		$ 0		$ 0

Note 3 - Fair Value of Financ_4

Note 3 - Fair Value of Financial Instruments - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Cash and cash equivalents		$ 1,130
Short-term investments	426,915	503,810
Total assets	426,915	504,940
Accrued warrant liability	24,461	78,637
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Cash and cash equivalents		1,130
Short-term investments
Total assets		1,130
Accrued warrant liability
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Cash and cash equivalents
Short-term investments	426,915	503,810
Total assets	426,915	503,810
Accrued warrant liability
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Cash and cash equivalents
Short-term investments
Total assets
Accrued warrant liability	$ 24,461	$ 78,637

Note 3 - Fair Value of Financ_5

Note 3 - Fair Value of Financial Instruments - Assumptions on Accrued Warrant Liability (Details) - Warrant [Member]	Sep. 30, 2019	Dec. 31, 2018
Measurement Input, Share Price [Member]
Stock Price	1.01	1.01
Measurement Input, Exercise Price [Member] | Minimum [Member]
Stock Price	3.64	3.64
Measurement Input, Exercise Price [Member] | Maximum [Member]
Stock Price	20.4	24.4
Measurement Input, Expected Term [Member] | Minimum [Member]
Stock Price	1.29	0.04
Measurement Input, Expected Term [Member] | Maximum [Member]
Stock Price	1.85	2.6
Measurement Input, Price Volatility [Member] | Minimum [Member]
Stock Price	0.7836	0.8807
Measurement Input, Price Volatility [Member] | Maximum [Member]
Stock Price	0.859	1.0818
Measurement Input, Expected Dividend Rate [Member]
Stock Price
Measurement Input, Discount Rate [Member] | Minimum [Member]
Stock Price	0.0165	0.0012
Measurement Input, Discount Rate [Member] | Maximum [Member]
Stock Price	0.0171	0.0248

Note 3 - Fair Value of Financ_6

Note 3 - Fair Value of Financial Instruments - Changes in Fair Value of Level 3 Fair Value Measurements (Details) - Accrued Warrant Liability [Member] - USD ($)		3 Months Ended		9 Months Ended
		Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Beginning Balance		$ 60,993	$ 362,842	$ 78,637	$ 1,041,455
Total (gains) or losses, realized and unrealized, included in earnings (1)	[1]	(36,532)	(121,442)	(54,176)	(800,055)
Issuances
Settlements
Ending Balance		$ 24,461	$ 241,400	$ 24,461	$ 241,400
[1]	Unrealized gains or losses related to the accrued warrant liability were included as change in value of accrued warrant liability. There were no realized gains or losses for the three and nine months ended September 30, 2019 and 2018.

Note 4 - Stockholders' Equity_2

Note 4 - Stockholders' Equity (Details Textual) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	0	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	$ 0	$ 0
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	$ 0

Note 4 - Stockholders' Equity -

Note 4 - Stockholders' Equity - Option Activity (Details) - $ / shares	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Outstanding (in shares)	160,076
Outstanding, weighted average exercise price (in dollars per share)	$ 35.92
Granted (in shares)	0	0
Granted, weighted average exercise price (in dollars per share)
Vested (in shares)
Vested, weighted average exercise price (in dollars per share)
Forfeited, Canceled (in shares)	(23,787)
Forfeited, Canceled, weighted average exercise price (in dollars per share)	$ 11.85
Outstanding (in shares)	136,289
Outstanding, weighted average exercise price (in dollars per share)	$ 40.12

Note 4 - Stockholders' Equity_3

Note 4 - Stockholders' Equity - Summary of Outstanding Options (Details) - USD ($)	9 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Quantity, outstanding (in shares)	136,289	160,076
Quantity, vested (in shares)	136,289
Weighted Average Exercise Price, outstanding (in dollars per share)	$ 40.12	$ 35.92
Weighted Average Exercise Price, vested (in dollars per share)	$ 40.12
Weighted Average Remaining Contractual Term, outstanding (Year)	3 years 255 days
Weighted Average Remaining Contractual Term, vested (Year)	3 years 255 days
Intrinsic Value, outstanding
Intrinsic Value, vested

Note 5 - Warrants (Details Text

Note 5 - Warrants (Details Textual) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 8.89	$ 10.90
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 3.64
Warrants and Rights Outstanding, Term	1 year
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 20.40
Warrants and Rights Outstanding, Term	7 years

Note 5 - Warrants - Outstanding

Note 5 - Warrants - Outstanding Warrants (Details)	9 Months Ended
	Sep. 30, 2019$ / sharesshares
Warrants outstanding (in shares) | shares	528,054
Warrants outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 10.90
Warrants granted (in shares) | shares
Warrants granted, weighted average exercise price (in dollars per share) | $ / shares
Warrants exercised (in shares) | shares
Warrants exercised, weighted average exercise price (in dollars per share) | $ / shares
Warrants forfeited, canceled (in shares) | shares	(200,801)
Warrants forfeited, canceled, weighted average exercise price (in dollars per share) | $ / shares	$ 14.18
Warrants outstanding (in shares) | shares	327,253
Warrants outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 8.89

Note 6 - Significant Alliance_2

Note 6 - Significant Alliances and Related Parties (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Research and Development Expense, Total	$ 262,410	$ 839,413	$ 1,375,409	$ 3,084,790
RPCI [Member]
Research and Development Expense, Total	9,367	138,817	67,318	187,262
Accounts Payable, Related Parties	7,925	0	7,925	0
Due to Related Parties, Total	0	214,429	0	214,429
Royalty Expense			0	0
The Cleveland Clinic [Member]
Research and Development Expense, Total			30,710	0
BBL [Member]
Research and Development Expense, Total	129	122,929	129	454,937
Due to Related Parties, Total	0	53,000	0	53,000
Sublease and Other Income, Related Parties	0	11,553	20,808	34,659
Accounts Receivable, Related Parties, Gross	219,108	206,747	219,108	206,747
Accounts Receivable, Related Parties	16,957	4,596	16,957	4,596
Incuron [Member]
Sublease and Other Income, Related Parties	0	1,134	2,268	4,044
Accounts Receivable, Related Parties, Gross	32,512	13,457	32,512	13,457
Revenue from Related Parties	26,928	199,324	295,958	291,445
GPI [Member]
Sublease and Other Income, Related Parties	1,178	675	4,209	675
Related Party Transaction, Expenses from Transactions with Related Party	54,700	39,083	149,550	39,083
Accounts Payable and Accrued Liabilities, Total	$ 0	$ 20,853	$ 0	$ 20,853